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Mesenchymal stromal cells (MSCs) have been established as promising candidate sources of universal donor cells for cell therapy
due to their contributions to tissue and organ homeostasis, repair, and support by self-renewal andmultidifferentiation, as well as by
their anti-inflammatory, antiproliferative, immunomodulatory, trophic, and proangiogenic properties. Various diseases have been
treated byMSCs in animal models. Additionally, hundreds of clinical trials related to the potential benefits of MSCs are in progress.
However, although all MSCs are considered suitable to exert these functions, dissimilarities have been found amongMSCs derived
from different tissues. The same levels of efficacy and desired outcomes have not always been achieved in the diverse studies that
have been performed thus far. Moreover, autologous MSCs can be affected by the disease status of patients, compromising their
use. Therefore, collecting information regarding the characteristics of MSCs obtained from different sources and the influence of
the host (patient) medical conditions on MSCs is important for assuring the safety and efficacy of cell-based therapies. This review
provides relevant information regarding factors to consider for the clinical application of MSCs.
1. Introduction
MSCs are considered a heterogeneous population of non-
haematopoietic progenitor cells derived from the mesoder-
mal germ layer that have both self-renewal and multidiffer-
entiation [1] abilities. MSCs found in virtually all postnatal
organs and tissues [2] possess multifaceted features, making
them promising candidate sources of donor cells for use in
cell therapy and transplantation. MSCs function in the repair
and support of tissues, contributing to tissue homeostasis.
Although the exact origin of MSCs remains elusive, strong
evidence has indicated that MSC progenitors are in the
perivascular zone [3] in an environment that promotes a
quiescent-resting state, ensuring homeostasis maintenance.
When a tissue is damaged and the whole machinery of the
organism begins to operate the body’s repair mechanisms,
MSCs enter the blood stream and are attracted by proin-
flammatory cytokines at injury areas. Thus, MSCs have been
called “guardians of inflammation” [4]. The cytoskeleton,
extracellular matrix molecules, cell contacts, adhesion lig-
ands, and receptors are involved in the repair process [5].
Although the exact mechanisms related to the migration of
MSCs into specific sites and across the endothelial cell layer
remain unknown, chemokines and their receptors may play
roles in this process.
Although MSC survival, permanent engraftment, and
differentiation into resident cells was thought to be necessary
to obtain the beneficial effects of these cells initially, clinical
experience and several experiments have shown that one
of the primary functions of MSCs, most likely their key
function, is to secrete several bioactive molecules related to
the microenvironment in which these cells are immersed.
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Table 1: Summary of mesenchymal stroma cell nomenclature.
Nomenclature Year Authors’ references
CFU-F and osteogenic stem cells 1974 Friedenstein et al. [10]
Stromal stem cells 1988 Owen and Friedenstein [16]
Mesenchymal stem cells 1991 Caplan [17]
Mesenchymal progenitor cells 1999 Dennis et al. [18]
Skeletal stem cells 2000 Bianco and Robey [19]
MAPCs and mesodermal progenitor cells 2002 Jiang et al. [20]
Multipotent mesenchymal stromal cells 2006 Dominici et al. (ISCT) [21]
Medicinal signalling cells 2010 Caplan [22]
CFU-F: colony-forming unit fibroblasts; MAPCs: multipotent adult progenitor cells; ISCT: International Society for Cell Therapy.
MSCs secrete a wide variety of proinflammatory and anti-
inflammatory cytokines, chemokines, growth factors, and
prostaglandins under resting and inflammatory conditions
[6]. These molecules are associated with immunomodula-
tion (indoleamine-2,3-dioxygenase (IDO), prostaglandin-E2
(PGE-2), TGF-𝛽, HLA-G5, and HGF), antiapoptosis (VEGF,
GM-CSF, TGF-𝛽, Stanniocalcin-1, and IGF-I), angiogenesis
(VEGF, MCP-1, and IGF-I), local stem and progenitor cell
growth and differentiation support (SCF, Angiopoietin-1, and
SDF-1), antifibrosis (HGF and bFGF), and chemoattraction
(CCL2, CCL4, and CXCL12) [7]. Additionally, beneficial
effects of the use of MSC conditioned media (CM) have been
reported; even CM has been shown to be therapeutically
better than the cells themselves [8, 9].
However, although these properties are generally attrib-
uted to all MSCs derived from different tissues, evidence
from different studies has suggested that MSCs from diverse
sources are not identical and do not always achieve the same
efficacy levels and desired outcomes. Likewise, diverse donor
conditions can affect the MSC characteristics because the
environment “niche” in which MSCs are immersed may be
affected. In this review, wewill describe some of the biological
characteristics of MSCs that must be considered and the
effects of the disease status of donors and recipients on these
characteristics.
2. Biological Characteristics
2.1. Phenotypic Profile. Since Friedenstein and colleagues first
isolated a colony-forming unit fibroblast (CFU-F) from bone
marrow (BM) [10], bone marrow has been widely used as a
source of MSCs for many investigations and clinical trials.
In addition to bone marrow, MSCs have been isolated from
different tissues such as adipose tissue [11], umbilical cord
blood [12], dental pulp [13], synovial liquid and amniotic fluid
[14, 15]. All these tissues vary in their cellular components,
signals, and factors secreted, resulting in different immedi-
ate microenvironment conditions, thus developing several
physiological niches. Although isolated and long-term cul-
turedMSCs of most tissues show similar immunophenotypic
characteristics, some differences have been found among
MSCs of different tissue origins according to data obtained
by in vitro experiments. In 2006, the International Society
of Cellular Therapy (ISCT) published the minimal criteria
to define MSCs by nomenclature (Table 1) and by biological
characteristics [10, 16–22] to allow studies from different
groups to be compared and contrasted.These criteria include
the following: (i) coexpression of markers such as CD73,
CD90, and CD105 and a lack of expression of haematopoietic
markers (CD45, CD34, and CD14) and human leucocyte
antigen (HLA-DR), (ii) multipotent differentiation potential,
and (iii) adherence to plastic. However, several researchers
have noted that adipose-tissue-derived MSCs (AD-MSCs)
express CD34 and CD54 in early passages [23] and have
lower expression of CD106 and that umbilical cord blood-
derived MSCs (UCB-MSCs) express CD90 and CD105 [24].
Other markers have been used in different studies, and
other differences have emerged, such as VEGFR-2 (Flk-1)
expression, which was significantly higher in periosteum-
derived cells compared to that in adipose tissue- and muscle-
derived cells, or the rate of NGFR positivity, which was much
higher in muscle-derived cells compared to that in other
mesenchymal tissue-derived cells [25].
Although some immunophenotypic differences have
been documented, many researchers consider the fact that
these differences could be due to distinct extraction methods
and different culture methodologies, resulting in variations
of MSC surface markers. Thus, this review aimed to further
investigate markers and characteristics that are more specific
to select the better sources of MSCs for clinical applications.
Likewise, expanding the cells in vitro is necessary to
obtain the desired numbers for therapeutic approaches.
Changes in the proteomic phenotype of AD-MSCs have
been observed during passages [26], although no proper
approaches to examine the state of cells continuously during
long-term in vitro culture have been established. Some
researchers ascribe these variations to the adaptation of
cells to the environment; thus, determining the biomolecular
markers that are involved in these variations is essential for
obtaining a better phenotypic characterisation of these cells
and thus for achieving more effective cell therapy in the
future.
2.2. MSC Proliferation. The proliferative activity of MSCs is
another feature thatmay be affected by the different origins of
MSCs. The rate and persistence of MSC proliferation appear
to vary between source tissues. MSCs are considered adult
stem cells, and, unlike embryonic stem cells (ESCs), these
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cells have a limited proliferative capacity. Physiological niches
maintain adult stem cells in an undifferentiated state; how-
ever, whenMSCs are cultured in vitro, they age, which affects
their therapeutic properties, such as alterations in phenotype,
differentiation potential, global gene expression patterns,
miRNA profiles [27], and even chromosomal abnormalities
[28], particularly after long-term culture or when cells of
multiple doublings are used. Large numbers of MSCs are
needed for therapeutic applications, and in vitro expansion is
required to produce the desiredMSCnumbers. In vivo, MSCs
represent 0.0001% of nucleated BM cells, and their number
decreases with the age of the donor. The quantity of MSCs
(CFU-Fs) among nucleated BM cells decreases with age from
oneMSC in 104 BM cells in newborns to oneMSC in 105 cells
in teenagers and to one MSC in 106 cells in older individuals
[29]. Furthermore, MSCs from older human donors differ
significantly from those fromyounger donors inmorphology,
replicative lifespan [30], doubling time, healing capacity [31],
and differentiation potential. Sufficient evidence has indi-
cated that MSCs from older donors have limited therapeutic
efficacy, and some studies have suggested that the difference
between preclinical and clinical findings is due to the donor
age. Therefore, considering that several age-related diseases
exist and that elderly patients are potential users of cell
therapy, understanding themolecular and biological effects of
ageing on MSCs is essential for developing safe and effective
MSC-based autologous cell therapy. Meanwhile, the use of
allogeneic MSCs may be a treatment option for these specific
patients. As we comment below, MSCs elude allogeneic
rejection, and their infusion is feasible andwell tolerated,with
no adverse effects [32, 33].
2.3. Differentiation Capacity. MSCs have the ability to differ-
entiate in vitro into several mesenchymal lineages including
adipose tissue, bone, cartilage, and muscle [15, 34, 35].
Furthermore, MSCs can differentiate into endothelial cells,
neurons, and glial cells because MSCs express genes related
to specific lineages rather than to those of the mesenchymal
lineage [36]. Althoughmultilineage differentiation is another
minimal criterion advised by the ISCT and undoubtedly
represents a fundamental property of MSCs, this ability
depends primarily on the source tissue from which these
cells are derived. As discussed by Sakaguchi et al. [25], who
compared human MSCs isolated from bone marrow, syn-
ovium, periosteum, skeletal muscle, and adipose tissue and
expanded them by similar processes, synovium-derived cells
have the greatest ability for chondrogenesis; adipose- and
synovium-derived cells have the greatest ability for adipogen-
esis; and bone marrow-, synovium-, and periosteum-derived
cells have the greatest ability for osteogenesis. In another
comparative analysis, UCB-MSCs showed no adipogenic dif-
ferentiation capacity in contrast to BM- and AT-MSCs [37].
As discussed by Horwitz et al. [38], who used differentiated
MSCs in a study to test the regeneration of damaged tissues,
BM-MSCs can engraft after transplantation, differentiate to
functional osteoblasts and contribute to the formation of new
dense bone in children with osteogenesis imperfecta. Most
likely, themicroenvironment inwhichMSCs are transplanted
directly influences their distinct differentiation pathways.
New insights into the biological characteristics of MSCs are
needed to achieve future therapies.
2.4. Immunomodulatory Actions. Immunomodulatory prop-
erties of MSCs and their immunoprivileged condition make
these cells good candidates for use in several clinical trials
related to chronic, inflammatory, and autoimmune diseases.
MSCs interact with cells of the innate or adaptive immune
system (T cells, B cells, NK cells, monocyte-derived dendritic
cells, and neutrophils) [39, 40]. For a cell to be recognised
by the immune system, the expression of major histocom-
patibility complex (MHC) and costimulatory molecules is
necessary.MHC class I and class II human leukocyte antigens
(HLAs) aremaster triggers of robust immunological rejection
of grafts because they present antigens to cytolytic T lympho-
cytes (CTL) [41]. Human mesenchymal stem cells (hMSCs)
are characterised by low expression of MHC class I HLAs
but are constitutively negative for class II HLCs; these cells
do not express costimulatory molecules such as B7-1, B7-2,
CD80, CD86, CD40, and CD40L [42]. However, similar to
the thymic epithelium, MSCs express the surface markers
VCAM-1, ICAM-2, and LFA-3 [42, 43], which are crucial
for T cell interactions. Although a T cell response should
be expected, hMSCs are able to modulate the activation
and proliferation of both CD4+ and CD8+ cells in vitro by
arresting T cells in G0/G1 phase [44, 45]. Different studies
have suggested that cell-cell interactions and certain soluble
factors are the mechanisms used by MSCs to mediate the
immune response. Factors such as IDO, TGF-𝛽1, IFN-𝛾, IL-
1𝛽, TNF𝛼, IL-6, IL-10, PGE-2, HGF, andHLA-G5 are secreted
by MSCs or released after interactions with target cells. As
we mentioned above, MSCs remain in a resting state, display
antiapoptotic properties and maintain different cells such as
haematopoietic stem cells (HSCs), thus contributing to tissue
homeostasis. However, in an inflammatory environment
such as that created by cytokines such as IFN-𝛾, TNF-𝛼,
IL-1𝛼, and IL-1𝛽, MSCs begin to exert their immunosup-
pressive effects and polarise, inhibiting the proliferation of
effector cells and their production of cytokines. In this
regard, IFN-𝛾 is postulated as a “licensing” agent for MSC
antiproliferative action. MSCs may also acquire behaviour as
antigen-presenting cells (APCs) under certain concentrations
of IFN-𝛾 [46, 47]. However, no consensus regarding what
concentration of IFN-𝛾 is more necessary for MSCs to show
that inhibitory or APC functions exists. Likewise, TNF-𝛼
is another proinflammatory cytokine involved in the MSC
immune response, and TNF-𝛼 enhances the effect of IFN-𝛾
[48]. IFN-𝛾, with orwithout the help of TNF-𝛼, stimulates the
production of IDO by MSCs, inhibiting the proliferation of
activated T or NK cells [49] and thus enhancing the homing
potential and reparative properties of these cells; however,
somepotential risks are associatedwith the role of IFN-𝛾 [50].
Some authors have maintained that the immunomodula-
tory properties of MSCs are comparable [51, 52], while others
have argued that MSCs of different tissue origins or species
cannot have equivalent immunomodulatory properties [53,
54]. For example, MSCs from perinatal sources (umbilical
cord and amniotic membrane) show a higher immunomod-
ulatory capacity, differential gene expression profiles, and
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paracrine factor secretion compared to BM-MSCs [55].
Interestingly, in 2012, Lee and colleagues found that HLA-G,
a specific MHC-I antigen that is critical for maintaining the
immune-tolerant state of pregnancy and that is a contributing
factor to the induction of stronger immunosuppression [56],
is strongly positive only in placenta-derived MSCs (PD-
MSCs) in contrast to BM-MSCs and AD-MSCs, suggesting
that the immunophenotype of PD-MSCs may be superior to
other MSCs in terms of their immunosuppressive function
[57]. Nevertheless, in another related study, BM-MSCs were
more immunomodulatory than PD-MSCs [58]. Melief et al.
[59] concluded that the immunomodulatory capacities of
BM-MSCs and AD-MSCs are similar but that differences
in cytokine secretion cause AD-MSCs to have more potent
immunomodulatory effects than BM-MSCs.
A 2002 study showed that allogeneic MSCs prolonged
skin graft survival in baboons [60]. Mouse MSCs have
been used in related experiments; these cells use inducible
nitric oxide synthase (iNOS) for immunosuppression instead
of IDO. These findings indicate that MSCs differ between
species [61]. Since then, several preclinical models have been
used to analyse the biological effects of MSCs and their
ability to modulate immune responses, considering that not
all animal models mimic human diseases.
Once more, these differences could be due to isolation
procedures, to culture methodology, or, more likely, to diff-
erences in the microenvironments where cells reside. These
and other findings lead us to believe that determining
whether these differences may be relevant for their clinical
applications and whether MSCs of a particular tissue type
are more appropriate for specific therapies or diseases is
important.
3. Preclinical Applications
Preclinical models are essential for clinicians, researchers,
and both national and international regulatory agencies to
demonstrate the safety and efficacy of MSC-based therapies
[62]. Because MSCs are able to exert immunomodulatory
properties and to act on different immune cells both in vitro
and in vivo as mentioned above, these cells have begun to be
used against autoimmune diseases based on various autoim-
mune experimental models. Pioneer studies in experimental
autoimmune encephalomyelitis (EAE), a model for multiple
sclerosis, reported that MSCs derived from various tissue
origins show efficacy against neurodegenerative disorders
[63–68]. BM-MSC and UCB-MSC treatments have brought
about improvements in clinical and laboratory parameters in
systemic lupus erythematosus (SLE) [33, 69]. Furthermore,
ameliorating effects have been observed in experimental
mouse models of rheumatoid arthritis (RA) [70]. Diabetes
is another autoimmune disorder in which MSCs have been
employed [71–73]. Although promising results and progress
have been observed in this field, the interspecies differences
and contradictory experimental outcomes, as well as the
inability to recreate the complete pathophysiology of some
diseases, make it necessary to search for new animal models
to yield comparable results.
4. Autoimmune Diseases
MSCs are being used to facilitate the engraftment of trans-
planted HSCs and to treat graft-versus-host disease (GVHD)
after allogeneic haematopoietic stem cell transplantation
(HSCT) based on their immunomodulatory properties and
their ability to provide appropriate conditions; however,
preclinical and clinical experiments with MSCs do not
always show similar results for the prevention and treatment
of GVHD. In a study using a mouse model of GVHD
[74], MSCs suppressed alloantigen-induced T cell prolif-
eration in vitro in a dose-dependent manner but yielded
no clinical benefit regarding the incidence or severity of
GVHD. Instead, when UCB-MSCs were administered in
weekly doses in a xenogeneic model of GVHD, a marked
decrease in human T cell proliferation was observed, and
none of the mice developed GVHD. No therapeutic effect
was obtained when UCB-MSCs were administered at the
onset of GVHD [75]. In the same line of research, serial
infusions of mouse AD-MSCs could efficiently control the
lethal GVHD that occurred in recipients transplanted with
haploidentical haematopoietic grafts [76]. Mixed results have
also been achieved in human patients. One study found
that the cotransplantation of culture-expanded MSCs and
HSCs from HLA-identical sibling donors after myeloabla-
tive therapy accelerated haematopoietic engraftment [77];
however, a significant reduction of GVHD symptoms was
not shown, although the incidence or severity of GVHD
did not increase. Koc¸ et al. [78] reported a positive impact
of MSCs on haematopoiesis; rapid haematopoietic recovery
was observed in a clinical study with breast cancer patients
who received autologous HSCT together with autologous
MSCs. Therapeutic effects have also been reported at the
onset of GVHD, such as the case of a 9-year-old boy with
severe treatment-resistant GVHD after allogeneic HSCT for
acute lymphocytic leukaemia who received haploidentical
MSCs derived from his mother. He showed improvement
after 2MSC administrations [79]. Similar results have been
obtained in steroid-refractory GVHD pilot studies with BM-
MSCs and AD-MSCs [80, 81]. Several infusions appear to
be required to maintain the level of active immunomodula-
tion by MSCs. Similarly, the expression of proinflammatory
cytokines such as IFN-𝛾 in the environment at the time of
MSC administration is required by these cells to exert their
immunosuppressive effect because a lack of MSC “licensing”
can result in the absence of the desired therapeutic effect.
While evidence that MSCs are effective in combination
or after HSCT in specific haematological and nonhaema-
tological diseases has been shown, adverse reactions and
risk factors intrinsic to this practice have been reported.
In a pilot study, HLA-identical sibling-matched HSCs were
transplanted with or without MSCs in haematological malig-
nancy patients. Although MSCs were well tolerated and this
treatment effectively prevented GVHD, six patients (60%) in
theMSCgroup and three (20%) in the non-MSCgrouphad 3-
year disease-free survival rates of 30 and 66.7%, respectively
[82]. The relapse rate in the experimental group was higher
than that in the control group, suggesting that MSCs may
impair the therapeutic graft-versus-leukaemia (GVL) effect.
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In vitro and in vivo studies regarding the relationship between
the immunosuppressive properties of MSCs and the stimu-
lation of cancer growth have been performed. Mouse MSCs
fromBM, spleen, and thymus thatwere injected togetherwith
a genetically modified tumour cell vaccine could equally pre-
vent the onset of an antitumour memory immune response,
thus leading to tumour growth in normally resistant mice
[83]. In another in vivo experiment with a murine melanoma
tumour model, the authors observed that the subcutaneous
injection of B16 melanoma cells led to tumour growth in
allogeneic recipients only when MSCs were coinjected [84].
The functions of MSCs can be influenced by the existing
microenvironment, making them acquire supportive prop-
erties towards cancer cells and decrease immune reactions
[85]. Therefore, potential risks, related to the growth support
and enhancement of undetected or “resident” cancer, do exist,
and the administration of MSCs in these patients must be
thoroughly evaluated.
5. Do MSCs Carry out the Patient’s Disease?
One of the strategies to obtainMSCs for therapeutic purposes
is an autologous approach. These cells are collected from
patients by more or less invasive methods, isolated, seeded
in culture under goodmanufacturing practice (GMP) quality
standards, and reinjected into the patient. Nevertheless,
when the repair mechanisms of the body are insufficient or
ineffective, this treatment results in a homeostatic imbalance
in the organism, producing degradation and disease and
compromising the pool of endogenous cells, thus resulting in
low efficacy. Some diseases provoke changes in the bonemar-
row microenvironment, which is one of the primary sources
of MSCs, thus producing changes in the endogenous pool of
MSCs and altering their biological features [86]. MSCs from
patients with acute myeloid leukaemia showed abnormal
biological properties, includingmorphological heterogeneity,
limited proliferation capacity, and impaired differentiation
and haematopoiesis support ability [87]. MSCs derived from
patients with multiple myeloma showed impaired immune-
inhibitory effects on T cells, decreasing their osteogenic
potential [88]. Poor proliferation, differentiation potentials,
and cytokine release defects were found in BM-MSCs derived
from patients with aplastic anaemia, another haematopoietic
disorder [89, 90].
Although the mechanisms remain unknown, MSCs ap-
pear to be involved in autoimmune pathologies. For instance,
MSCs derived from patients with autoimmune diseases
display the following altered functions. (i) MSCs from
rheumatoid arthritis (RA) patients have an impaired abil-
ity to support haematopoiesis [91] and lower proliferative
and clonogenic potentials [92]. (ii) MSCs from immune
thrombocytopenic purpura (ITP) patients have a reduced
proliferative capacity and a lower inhibitory effect on T
cell proliferation compared with MSCs from healthy donors
[93]. (iii) MSCs from systemic lupus erythematosus (SLE)
patients display deficient growth, abnormal morphology, and
upregulated telomerase activity [94, 95]. (iv) MSCs from
systemic sclerosis (SSc) patients display early senescence
[96]. In metabolic diseases such as diabetes, alterations in
autologous MSCs have also been documented. A study using
MSCs from type 2 diabetic mice showed that the number of
these cells was diminished and that their proliferation and
survival abilities were impaired in vitro. Moreover, diabetic
MSC engraftment produced limited improvement in the
diabetic subjects and could not produce the same therapeutic
outcomes as in their nondiabetic counterparts in vivo [97].
Advanced glycation end products (AGEs) accumulate in the
tissues of aged people, and these products are involved in
diabetes and inmusculoskeletal diseases. In 2005, Kume et al.
[98] investigated the effect of AGEs onMSCs and showed that
AGEs inhibited MSC proliferation, induced MSC apoptosis,
and interfered with MSC differentiation into adipose tissue,
cartilage, and bone. Another study examined type 2 diabetes-
derived AD-MSCs and found that these cells had functional
impairments in their multilineage potential and proliferative
capacity because of prolonged exposure to high glucose
concentrations [99]. We demonstrated that diabetic-derived
AD-MSCs have an altered phenotype related to plasminogen
activator inhibitor-1 (PAI-1) expression levels and display
reduced fibrinolytic activity [100]. In this respect, our pre-
liminary results and others suggest that the immunogenicity
of MSCs could have related effects on the coagulation system
[101, 102].Thus,MSC-based therapy could lead to thrombotic
events in particular recipients.
Although the possibility of healing with our own cells is
extremely attractive, little is known regarding the influence
of different disease states and concomitant medications on
MSCs [103, 104]. Thus, although the use of autologous MSCs
for cell therapy is widespread, their use in humans must be
handled with extreme caution. Researching and analysing
both the risks and benefits of this therapy in individual
patients and for each disease state are necessary.
6. Safety and Efficacy in Clinical Trials
Several clinical trials are in progress to ensure the safety
and efficacy of MSCs used as medicaments. For cell-based
products, we must consider that cells are living products
and that their interactions with body fluids remain unclear
[100, 102, 105].
Phase I clinical trials are the first step in the investigation
of a new drug and include pharmacokinetic and pharmaco-
dynamic studies inwhich the patient’s safety plays an essential
role in the development of medicaments.The primary goal of
phase II clinical trials is to provide preliminary information
regarding the drug efficacy and safety supplement data
obtained in phase I trials. Usually, safety evaluations are
based on possible complications derived from the procedure
in a time-dependent manner after the administration of
the cells. Efficacy parameters focus on the improvement
of clinical effects at a given time. MSC-based cell therapy
is a relatively new therapeutic option for certain diseases,
and data regarding the long-term monitoring of patients
remain lacking. Nevertheless, the administration of MSCs
is considered a feasible and safe procedure with no adverse
events reported. However, the risks associated with stem cell
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Table 3: MSC cell-based therapies with a valid marketing authorisation.
Trade name Company Authorised by Cell type Indication
Hearticellgram∗ FCB PharmiCell KFDA (2011) Autologous BM-derived MSCs Treatment for postacutemyocardial infarction
Cartistem∗ Medipost KFDA (2012) Allogeneic hUCB-MSCs Treatment of traumatic anddegenerative osteoarthritis
Prochymal∗ Osiris Therapeutics Inc. Health Canada (2012)New Zealand (2012) Allogeneic BM-MSCs
Treatment of acute GvHD
children who are unresponsive to
steroids
MSCs: mesenchymal stem cells; BM: bone marrow; hUCB: human umbilical cord blood; GvHD: graft-versus-host disease; KFDA: Korean Food and Drug
Administration.
∗SCTMP: somatic cell therapy medicinal product.
therapy [106]must be considered because these risks increase
the probability of the occurrence of an adverse event.The cell
source, donor origin, product manufacturing, and recipient
disease status are important factors related to the safety and
efficacy of the use of MSCs. In this regard, the use of bovine
proteins in the medium used to culture these cells [38] and
the observed formation of ectopic tissue in animal models
[107, 108], as well as malignant transformation [109, 110] and
immune responses, must be evaluated before wider clinical
applications and registration are accepted.
7. Clinical Manufacturing of
MSC-Based Medicines
With the exception of haematopoietic stem cell transplants,
stem cell therapies used for the treatment of any disease
are considered drugs; therefore, their development, approval,
and use must be in accordance with specific standards
established for such medicines nationally and internation-
ally. MSCs are called advanced therapy medicinal products
(ATMPs) and are under regulation number 1394/2007. Relat-
ing production processes and development staff, clinicians,
and researchers is obligatory to achieve GMP procedures
under European regulations [111, 112]. Currently, no standard-
ised manufacturing platform exists, although most facilities
employ standard release criteria to measure sterility, viabil-
ity, and chromosomal stability to meet European or FDA
regulations [113]. Although regulation establishes common
parameters to follow, different protocols are used to isolate
these cells, and the processes, plating densities, and reagents
used cause the results to differ from each other. Donor selec-
tion in terms of age and disease status is another variable to
consider due to known MSC donor-to-donor heterogeneity
[114].The cell source is another important factor related to the
efficacy of the product. As reported previously, MSCs derived
from different tissues do not always achieve the same level of
efficacy. Additionally, culture media used for the production
of MSCs could affect the basic characteristics of cells; thus,
designing a fully defined medium free of animal and human
origins is crucial.
Thus far, noMSC-basedmedicine product has marketing
authorisation in the European Union, although four gene
and cell-based products have a valid marketing authorisation
awarded by the European Medicines Agency. However, since
2011, three MSC products have received marketing approval
in other regions [115] (Tables 2 and 3).
The MSC field continues its upward progression, with
a growing number of established companies and ongoing
clinical trials, but remaining challenges must be overcome.
Bottlenecks exist regarding donor selection, cells sources,
isolation protocols, culture media used, open-culture sys-
tems, bioreactors, and recipient disease status. Establishing a
standardised and comparable process is also crucial to ensure
biological and functional equivalence between product lots.
8. Concluding Remarks and
Future Perspectives
Treatments based on the use of human stem cells are novel
and promising therapeutic alternatives for some diseases.
Spain is at the forefront of research using such treatments,
and these treatments are developed and evaluated with
great scientific rigor. Currently, the use of living cells as a
medicinal product is becoming realistic. Cell therapy should
be safe, pure, stable and efficient. Cell-based products are
more complex and depend on the physiological and genetic
heterogeneity of the patient. Obtaining as much information
as possible with the tools we have at our disposal is essential
for ensuring the safety, reliability, quality, and effectiveness of
the manufactured product. MSCs are leading the way into
a new era of regenerative medicine, and their multifaceted
features make them powerful candidates to become tools
to treat several diseases. However, their indiscriminate use
has resulted in mixed outcomes in preclinical and clinical
studies. While MSCs derived from diverse tissues share some
common properties, they markedly differ in terms of their
differentiation abilities, growth rates, healing capacity, and
gene expression profile. Similarly, the disease statuses of
donors and recipients are important factors to consider when
using MSCs as therapeutic agents because factors such as
the MSC behaviour with body fluids and specific disease
environments remain unclear. Available data suggest that
some tissue-specific MSCs are more appropriate than others
according to particular pathologies. Equally, some evidence
has indicated that certain patient profiles are not suitable to
be treated with these therapies. Thus, multiple bottlenecks
for the standardisation of therapeutic protocols exist. Future
well-designed clinical trials and long-term monitoring of
Stem Cells International 9
patients are crucial for obtaining additional information
regarding the therapeutic use of MSCs.
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